Cargando…

Proteomic Signature of Extracellular Vesicles for Lung Cancer Recognition

The proteins of extracellular vesicles (EVs) that originate from tumors reflect the producer cells’ proteomes and can be detected in biological fluids. Thus, EVs provide proteomic signatures that are of great interest for screening and predictive cancer diagnostics. By applying targeted mass spectro...

Descripción completa

Detalles Bibliográficos
Autores principales: Novikova, Svetlana E., Soloveva, Natalia A., Farafonova, Tatiana E., Tikhonova, Olga V., Liao, Pao-Chi, Zgoda, Victor G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8539600/
https://www.ncbi.nlm.nih.gov/pubmed/34684727
http://dx.doi.org/10.3390/molecules26206145
_version_ 1784588786311626752
author Novikova, Svetlana E.
Soloveva, Natalia A.
Farafonova, Tatiana E.
Tikhonova, Olga V.
Liao, Pao-Chi
Zgoda, Victor G.
author_facet Novikova, Svetlana E.
Soloveva, Natalia A.
Farafonova, Tatiana E.
Tikhonova, Olga V.
Liao, Pao-Chi
Zgoda, Victor G.
author_sort Novikova, Svetlana E.
collection PubMed
description The proteins of extracellular vesicles (EVs) that originate from tumors reflect the producer cells’ proteomes and can be detected in biological fluids. Thus, EVs provide proteomic signatures that are of great interest for screening and predictive cancer diagnostics. By applying targeted mass spectrometry with stable isotope-labeled peptide standards, we assessed the levels of 28 EV-associated proteins, including the conventional exosome markers CD9, CD63, CD81, CD82, and HSPA8, in vesicles derived from the lung cancer cell lines NCI-H23 and A549. Furthermore, we evaluated the detectability of these proteins and their abundance in plasma samples from 34 lung cancer patients and 23 healthy volunteers. The abundance of TLN1, TUBA4A, HSPA8, ITGB3, TSG101, and PACSIN2 in the plasma of lung cancer patients was measured using targeted mass spectrometry and compared to that in plasma from healthy volunteers. The most diagnostically potent markers were TLN1 (AUC, 0.95), TUBA4A (AUC, 0.91), and HSPA8 (AUC, 0.88). The obtained EV proteomic signature allowed us to distinguish between the lung adenocarcinoma and squamous cell carcinoma histological types. The proteomic cargo of the extracellular vesicles represents a promising source of potential biomarkers.
format Online
Article
Text
id pubmed-8539600
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85396002021-10-24 Proteomic Signature of Extracellular Vesicles for Lung Cancer Recognition Novikova, Svetlana E. Soloveva, Natalia A. Farafonova, Tatiana E. Tikhonova, Olga V. Liao, Pao-Chi Zgoda, Victor G. Molecules Article The proteins of extracellular vesicles (EVs) that originate from tumors reflect the producer cells’ proteomes and can be detected in biological fluids. Thus, EVs provide proteomic signatures that are of great interest for screening and predictive cancer diagnostics. By applying targeted mass spectrometry with stable isotope-labeled peptide standards, we assessed the levels of 28 EV-associated proteins, including the conventional exosome markers CD9, CD63, CD81, CD82, and HSPA8, in vesicles derived from the lung cancer cell lines NCI-H23 and A549. Furthermore, we evaluated the detectability of these proteins and their abundance in plasma samples from 34 lung cancer patients and 23 healthy volunteers. The abundance of TLN1, TUBA4A, HSPA8, ITGB3, TSG101, and PACSIN2 in the plasma of lung cancer patients was measured using targeted mass spectrometry and compared to that in plasma from healthy volunteers. The most diagnostically potent markers were TLN1 (AUC, 0.95), TUBA4A (AUC, 0.91), and HSPA8 (AUC, 0.88). The obtained EV proteomic signature allowed us to distinguish between the lung adenocarcinoma and squamous cell carcinoma histological types. The proteomic cargo of the extracellular vesicles represents a promising source of potential biomarkers. MDPI 2021-10-12 /pmc/articles/PMC8539600/ /pubmed/34684727 http://dx.doi.org/10.3390/molecules26206145 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Novikova, Svetlana E.
Soloveva, Natalia A.
Farafonova, Tatiana E.
Tikhonova, Olga V.
Liao, Pao-Chi
Zgoda, Victor G.
Proteomic Signature of Extracellular Vesicles for Lung Cancer Recognition
title Proteomic Signature of Extracellular Vesicles for Lung Cancer Recognition
title_full Proteomic Signature of Extracellular Vesicles for Lung Cancer Recognition
title_fullStr Proteomic Signature of Extracellular Vesicles for Lung Cancer Recognition
title_full_unstemmed Proteomic Signature of Extracellular Vesicles for Lung Cancer Recognition
title_short Proteomic Signature of Extracellular Vesicles for Lung Cancer Recognition
title_sort proteomic signature of extracellular vesicles for lung cancer recognition
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8539600/
https://www.ncbi.nlm.nih.gov/pubmed/34684727
http://dx.doi.org/10.3390/molecules26206145
work_keys_str_mv AT novikovasvetlanae proteomicsignatureofextracellularvesiclesforlungcancerrecognition
AT solovevanataliaa proteomicsignatureofextracellularvesiclesforlungcancerrecognition
AT farafonovatatianae proteomicsignatureofextracellularvesiclesforlungcancerrecognition
AT tikhonovaolgav proteomicsignatureofextracellularvesiclesforlungcancerrecognition
AT liaopaochi proteomicsignatureofextracellularvesiclesforlungcancerrecognition
AT zgodavictorg proteomicsignatureofextracellularvesiclesforlungcancerrecognition